467 related articles for article (PubMed ID: 7905786)
21. Reversal of Vinca alkaloid resistance by anti-P-glycoprotein monoclonal antibody HYB-241 in a human tumor xenograft.
Rittmann-Grauer LS; Yong MA; Sanders V; Mackensen DG
Cancer Res; 1992 Apr; 52(7):1810-6. PubMed ID: 1348013
[TBL] [Abstract][Full Text] [Related]
22. In vivo characterization of P388 leukemia resistant to mitomycin C.
Rose WC; Huftalen JB; Bradner WT; Schurig JE
In Vivo; 1987; 1(1):47-52. PubMed ID: 2979764
[TBL] [Abstract][Full Text] [Related]
23. Sequential emergence of distinct resistance phenotypes in murine erythroleukemia cells under adriamycin selection: decreased anthracycline uptake precedes increased P-glycoprotein expression.
Slapak CA; Daniel JC; Levy SB
Cancer Res; 1990 Dec; 50(24):7895-901. PubMed ID: 1979251
[TBL] [Abstract][Full Text] [Related]
24. Reversal of multidrug resistance by RU 486.
Gruol DJ; Zee MC; Trotter J; Bourgeois S
Cancer Res; 1994 Jun; 54(12):3088-91. PubMed ID: 7911394
[TBL] [Abstract][Full Text] [Related]
25. Retroviral coexpression of two different types of drug resistance genes to protect normal cells from combination chemotherapy.
Suzuki M; Sugimoto Y; Tsukahara S; Okochi E; Gottesman MM; Tsuruo T
Clin Cancer Res; 1997 Jun; 3(6):947-54. PubMed ID: 9815770
[TBL] [Abstract][Full Text] [Related]
26. Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91.
Sugimoto Y; Tsukahara S; Sato S; Suzuki M; Nunoi H; Malech HL; Gottesman MM; Tsuruo T
J Gene Med; 2003 May; 5(5):366-76. PubMed ID: 12731085
[TBL] [Abstract][Full Text] [Related]
27. [The cross resistance to cytostatics of leukemia P388 cells with induced resistance to doxorubicin].
Donenko FV; Sitdikova SM; Kabieva AO
Biull Eksp Biol Med; 1993 Sep; 116(9):309-11. PubMed ID: 8118011
[TBL] [Abstract][Full Text] [Related]
28. Resistance to TNF-alpha and adriamycin in the human breast cancer MCF-7 cell line: relationship to MDR1, MnSOD, and TNF gene expression.
Zyad A; Bénard J; Tursz T; Clarke R; Chouaib S
Cancer Res; 1994 Feb; 54(3):825-31. PubMed ID: 7905787
[TBL] [Abstract][Full Text] [Related]
29. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.
Mirski SE; Evans CD; Almquist KC; Slovak ML; Cole SP
Cancer Res; 1993 Oct; 53(20):4866-73. PubMed ID: 8104687
[TBL] [Abstract][Full Text] [Related]
30. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.
Boesch D; Gavériaux C; Jachez B; Pourtier-Manzanedo A; Bollinger P; Loor F
Cancer Res; 1991 Aug; 51(16):4226-33. PubMed ID: 1678313
[TBL] [Abstract][Full Text] [Related]
31. Scanning electron microscopy of multidrug resistant cells in haematological and mammary malignancies.
Galimberti S; Bianchi F; Bernardini N; Mattii L; Dolfi A; Lupetti M; Petrini M
Cell Mol Biol (Noisy-le-grand); 1993 Jul; 39(5):543-51. PubMed ID: 8104068
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides.
Cucco C; Calabretta B
Cancer Res; 1996 Oct; 56(19):4332-7. PubMed ID: 8813118
[TBL] [Abstract][Full Text] [Related]
33. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanisms.
Marchini S; Damia G; Broggini M; Pennella G; Ripamonti M; Marsiglio A; Geroni C
Cancer Res; 2001 Mar; 61(5):1991-5. PubMed ID: 11280757
[TBL] [Abstract][Full Text] [Related]
34. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
35. Overcoming drug resistance in cancer cells with synthetic isoprenoids.
Yamaguchi T; Nakagawa M; Shiraishi N; Yoshida T; Kiyosue T; Arita M; Akiyama S; Kuwano M
J Natl Cancer Inst; 1986 May; 76(5):947-53. PubMed ID: 3457980
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.
Hyafil F; Vergely C; Du Vignaud P; Grand-Perret T
Cancer Res; 1993 Oct; 53(19):4595-602. PubMed ID: 8402633
[TBL] [Abstract][Full Text] [Related]
37. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance.
Ford JM; Prozialeck WC; Hait WN
Mol Pharmacol; 1989 Jan; 35(1):105-15. PubMed ID: 2563302
[TBL] [Abstract][Full Text] [Related]
38. Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model.
Iwahashi T; Okochi E; Ariyoshi K; Watabe H; Amann E; Mori S; Tsuruo T; Ono K
Cancer Res; 1993 Nov; 53(22):5475-82. PubMed ID: 8106147
[TBL] [Abstract][Full Text] [Related]
39. Chemoprotection effect of multidrug resistance 1 (MDR1) gene transfer to hematopoietic progenitor cells and engrafted in mice with cancer allows intensified chemotherapy.
Guo C; Jin X
Cancer Invest; 2006 Nov; 24(7):659-68. PubMed ID: 17118775
[TBL] [Abstract][Full Text] [Related]
40. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening.
Wu L; Smythe AM; Stinson SF; Mullendore LA; Monks A; Scudiero DA; Paull KD; Koutsoukos AD; Rubinstein LV; Boyd MR
Cancer Res; 1992 Jun; 52(11):3029-34. PubMed ID: 1350507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
